NASDAQ:YMAB - Y-mAbs Therapeutics Stock Price, Forecast & News

Y-mAbs Therapeutics trades on the NASDAQ under the ticker symbol "YMAB."

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) announced its earnings results on Wednesday, November, 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.16. View Y-mAbs Therapeutics' Earnings History.

Y-mAbs Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 27th 2020. View Earnings Estimates for Y-mAbs Therapeutics.

5 brokers have issued 12 month price objectives for Y-mAbs Therapeutics' stock. Their forecasts range from $38.00 to $41.00. On average, they expect Y-mAbs Therapeutics' share price to reach $39.50 in the next twelve months. This suggests a possible upside of 14.6% from the stock's current price. View Analyst Price Targets for Y-mAbs Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Y-mAbs Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Y-mAbs Therapeutics.

News stories about YMAB stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Y-mAbs Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Y-mAbs Therapeutics.

Y-mAbs Therapeutics saw a drop in short interest in January. As of January 31st, there was short interest totalling 1,500,000 shares, a drop of 9.1% from the January 15th total of 1,650,000 shares. Based on an average trading volume of 284,800 shares, the days-to-cover ratio is currently 5.3 days. Currently, 7.7% of the company's shares are short sold. View Y-mAbs Therapeutics' Current Options Chain.

Some companies that are related to Y-mAbs Therapeutics include United Therapeutics (UTHR), Global Blood Therapeutics (GBT), Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE) and Zai Lab (ZLAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Y-mAbs Therapeutics investors own include Bank of Hawaii (BOH), InterDigital Wireless (IDCC), Stag Industrial (STAG), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Crispr Therapeutics (CRSP), JD.Com (JD) and Nabriva Therapeutics (NBRV).

(YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Y-mAbs Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sofinnova Investments Inc. (5.52%), FMR LLC (3.50%), Alliancebernstein L.P. (2.13%), State Street Corp (1.88%), Goldman Sachs Group Inc. (1.45%) and Perceptive Advisors LLC (1.42%). Company insiders that own Y-mAbs Therapeutics stock include Ashu Tyagi, James Healy, Johan Wedell-Wedellsborg, Moller San Pedro Claus Juan and Thomas Gad. View Institutional Ownership Trends for Y-mAbs Therapeutics.

YMAB stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Renaissance Technologies LLC and Vident Investment Advisory LLC. Company insiders that have sold Y-mAbs Therapeutics company stock in the last year include Johan Wedell-Wedellsborg and Thomas Gad. View Insider Buying and Selling for Y-mAbs Therapeutics.

YMAB stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, State Street Corp, Goldman Sachs Group Inc., Driehaus Capital Management LLC, Sofinnova Investments Inc., Alliancebernstein L.P., AXA and Schonfeld Strategic Advisors LLC. Company insiders that have bought Y-mAbs Therapeutics stock in the last two years include Ashu Tyagi, James Healy and Moller San Pedro Claus Juan. View Insider Buying and Selling for Y-mAbs Therapeutics.

Shares of YMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of YMAB stock can currently be purchased for approximately $34.47.

Y-mAbs Therapeutics has a market capitalization of $1.37 billion. The company earns $-43,270,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Y-mAbs Therapeutics employs 32 workers across the globe.View Additional Information About Y-mAbs Therapeutics.

The official website for Y-mAbs Therapeutics is http://www.ymabs.com/.

Y-mAbs Therapeutics' mailing address is 230 Park Avenue Suite 3350, NEW YORK NY, 10169. The company can be reached via phone at 646-885-8505 or via email at [email protected]